Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates

被引：1

作者：

Papadimitrakopoulou, Vassiliki ^{[1
]}

Redman, Mary ^{[2
]}

Gandara, David R. ^{[3
]}

Hirsch, Fred R. ^{[4
]}

Mack, Philipp ^{[5
]}

Borghaei, Hossein ^{[6
]}

Langer, Corey ^{[7
]}

Wade, James ^{[8
]}

Edelman, Martin ^{[9
]}

Albain, Kathy ^{[10
]}

Lara, Primo ^{[5
]}

Aggarwal, Charu ^{[11
]}

Socinski, Mark ^{[12
]}

Gettinger, Scott ^{[13
]}

Bazhenova, Lyudmila ^{[14
]}

Malik, Shakun ^{[15
]}

Miller, Vincent ^{[16
]}

Mcdonough, Shannon ^{[17
]}

Sigal, Ellen V. ^{[2
]}

Kelly, Karen ^{[18
]}

Herbst, Roy ^{[19
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Friends Canc Res, Washington, DC USA

[3] UC Davis Comprehens Canc Ctr, Div Hem Oncol, Sacramento, CA USA

[4] Univ Colorado, Ctr Canc, Other, Aurora, CO USA

[5] UC Davis Comprehens Canc Ctr, Sacramento, CA USA

[6] Fox Chase Canc Ctr, Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[7] Univ Penn Hlth Syst, Hematol Oncol, Philadelphia, PA USA

[8] Heartland Ncorp, Decatur, IL USA

[9] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA

[10] Loyola Univ Chicago, Stritch Sch Med, Dept Med, Div Hematol Oncol, Maywood, IL USA

[11] Univ Penn, Hematol Oncol, Philadelphia, PA 19104 USA

[12] Univ Pittsburgh, Med, Pittsburgh, PA USA

[13] Yale Canc Ctr, New Haven, CT USA

[14] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[15] NCI, Ctep, NIH, Rockville, MD USA

[16] Fdn Med Inc, Clin Dev, Cambridge, MA USA

[17] Swog Stat Ctr, Seattle, WA USA

[18] UC Davis Comprehens Canc Ctr, Hematol Oncol, Sacramento, CA USA

[19] Yale Canc Ctr, Med Oncol, New Haven, CT USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

genomic screening; umbrella trial; S1400; Squamous cell lung cancer;

D O I：

10.1016/j.jtho.2016.11.513

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA16.10

引用

页码：S439 / S440

页数：2

共 47 条

[11] Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)
Vaidya, Riha
Unger, Joseph M.
Qian, Lu
Minichiello, Katherine
Herbst, Roy S.
Gandara, David R.
Neal, Joel W.
Leal, Ticiana A.
Patel, Jyoti D.
Dragnev, Konstantin H.
Waqar, Saiama N.
Edelman, Martin J.
Sigal, Ellen V.
Adam, Stacey J.
Malik, Shakun
Blanke, Charles D.
Leblanc, Michael L.
Kelly, Karen
Gray, Jhanelle E.
Redman, Mary W.
JCO PRECISION ONCOLOGY, 2023, 7
[12] Conduct of a precision medicine trial: screening, tissue adequacy, study registration, and reasons for not participating on lung-map (lung cancer master protocol)
Griffin, Katie
McDonough, Shannon
Miao, Jieling
Moon, James
Redman, Mary W.
TRIALS, 2017, 18
[13] A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol
Neal, Joel W.
Minichiello, Katherine
Brennick, Ryan
Huang, Richard S. P.
Hiemenz, Matthew C.
Amler, Cornel
Patel, Jyoti
Herbst, Roy
Reckamp, Karen L.
Borghaei, Hossein
Highleyman, Louise
Redman, Mary W.
Pasquina, Lincoln W.
Kozono, David E.
ONCOLOGIST, 2024, 29 (06): : e843 - e847
[14] Patients, Investigators and Pharmaceuticals Working Together to Accelerate Research and Access: The Lung Cancer Master Protocol (Lung-MAP) Clinical Trial
Norris, Kim
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S141 - S142
[15] Design, conduct, and analysis of a master protocol within an evolving landscape of standard of care: the lung-map trial
Redman, Mary
Moon, James
McDonough, Shannon
Miao, Jieling
Griffin, Katie
LeBlanc, Michael
TRIALS, 2017, 18
[16] Patient Knowledge and Expectations Related to Return of Genomic Results in the Lung-MAP (SWOG 1400) Biomarker-Driven Clinical Trial
Roth, J.
Trivedi, M.
Gray, S.
Patrick, D.
Burke, W.
Delaney, D.
Watabayashi, K.
Litwin, P.
Shah, P.
Crew, K.
Yee, M.
Redman, M.
Papadimitrakopoulou, V.
Kelly, K.
Gandara, D.
Hershman, D.
Ramsey, S.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S224 - S225
[17] Therapeutic utility of Lung-MAP: ushering into an era of genomic and biomarker-driven clinical trials
Chenyue Zhang
Haiyong Wang
Signal Transduction and Targeted Therapy, 6
[18] Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A
Hirsch, F.
Hua, X.
Wu, M.
Neal, J.
Cheng, H.
Gettinger, S.
Bazhenova, L.
Papadimitrakopoulou, V.
Borghaei, H.
Mack, P.
Kelly, K.
Herbst, R.
Gandara, D.
Redman, M.
Kozono, D.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S102 - S102
[19] Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G
Owonikoko, Taofeek K.
Redman, Mary W.
Byers, Lauren A.
Hirsch, Fred R.
Mack, Philip C.
Schwartz, Lawrence H.
Bradley, Jeffrey D.
Stinchcombe, Thomas E.
Leighl, Natasha B.
Al Baghdadi, Tareq
Lara, Primo, Jr.
Miao, Jieling
Kelly, Karen
Ramalingam, Suresh S.
Herbst, Roy S.
Papadimitrakopoulou, Vassiliki
Gandara, David R.
CLINICAL LUNG CANCER, 2021, 22 (03) : 187 - +
[20] Therapeutic utility of Lung-MAP: ushering into an era of genomic and biomarker-driven clinical trials
Zhang, Chenyue
Wang, Haiyong
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)

← 1 2 3 4 5 →